Factors That Favor the Occurrence of Cough in Patients Treated with Ramipril--a Pharmacoepidemiological Study

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2012 Sep 1

PMID 22936201

Citations 4

Authors

Katarzyna Wyskida

Edyta Jura-Szoltys

Mike Smertka

Aleksander Owczarek

Jerzy Chudek

Affiliations

Soon will be listed here.

Abstract

Background: Dry cough is a common cause for the discontinuation of ramipril treatment. The aim of this pharmacoepidemiological study was to assess the incidence of ramipril-related cough among the Polish population and to characterize patients at risk of experiencing the adverse effect of cough during ramipril treatment.

Material/methods: This was a prospective observational study involving 10,380 patients treated with ramipril for a period of no longer than 8 weeks, consisting of 3 visits: baseline, first follow-up (after 4-8 weeks) and second follow-up visit (after 4-8 weeks of cessation of ramipril, conducted only for evaluating coughing patients).

Results: The incidence of ramipril-related cough was 7.1%. Logistic regression analysis identified female sex (OR=1.35), cigarette smoking (OR=2.50), chronic obstructive pulmonary disease (OR=1.70), asthma (OR=1.60) and previous history of tuberculosis (OR=6.20) to be significantly and independently associated with the onset of ramipril-related cough. Coughing subsided within a period of 2-20 days after ramipril was discontinued. In all patients reporting the appearance of cough within the first 5 days after therapy initiation, the adverse effect subsided after therapy discontinuation. If cough appeared within 6-10 days, it subsided after discontinuation in 81.6% of subjects. Cough persisted in 30.4% of those reporting later onset.

Conclusions: 1. Female sex, cigarette smoking, COPD, asthma, and previous history of tuberculosis increase the risk of ramipril-related cough. 2. The later the cough occurs during treatment, the less often the drug is the causative agent and the cough and also less likely to disappear after discontinuation of ramipril.

Citing Articles

ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction.

Pinto B, Jadhav U, Singhai P, Sadhanandham S, Shah N Indian Heart J. 2020; 72(5):345-350.

PMID: 33189192 PMC: 7670268. DOI: 10.1016/j.ihj.2020.08.007.

Demographic and Clinical Characteristics of Patients Presenting With Angiotensin-converting Enzyme Inhibitors Induced Cough.

Jamshed F, Jaffry H, Hanif H, Kumar V, Naz U, Ahmed M Cureus. 2019; 11(9):e5624.

PMID: 31700727 PMC: 6822917. DOI: 10.7759/cureus.5624.

Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink.

Mahmoudpour S, Baranova E, Souverein P, Asselbergs F, de Boer A, Maitland-van der Zee A Br J Clin Pharmacol. 2016; 82(6):1647-1659.

PMID: 27524468 PMC: 5099558. DOI: 10.1111/bcp.13090.

Lung diffusion capacity in children with respiratory symptoms and untreated GERD.

Miric M, Turkalj M, Nogalo B, Erceg D, Perica M, Plavec D Med Sci Monit. 2014; 20:774-81.

PMID: 24816214 PMC: 4026150. DOI: 10.12659/MSM.890336.

References

McCarney R, Warner J, Iliffe S, Haselen R, Griffin M, Fisher P . The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol. 2007; 7:30. PMC: 1936999. DOI: 10.1186/1471-2288-7-30. View

Fogari R, Zoppi A, Tettamanti F, Malamani G, Tinelli C, Salvetti A . Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol. 1992; 19(5):670-3. View

Dicpinigaitis P . Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl):169S-173S. DOI: 10.1378/chest.129.1_suppl.169S. View

Morimoto T, Gandhi T, Fiskio J, Seger A, So J, Cook E . Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med. 2004; 19(6):684-91. PMC: 1492376. DOI: 10.1111/j.1525-1497.2004.30016.x. View

Simpson C, Amin M . Chronic cough: state-of-the-art review. Otolaryngol Head Neck Surg. 2006; 134(4):693-700. DOI: 10.1016/j.otohns.2005.11.014. View

Joe S, Thakkar K . Chronic rhinosinusitis and asthma. Otolaryngol Clin North Am. 2008; 41(2):297-309, vi. DOI: 10.1016/j.otc.2007.11.001. View

McEwan J, Choudry N, Street R, Fuller R . Change in cough reflex after treatment with enalapril and ramipril. BMJ. 1989; 299(6690):13-6. PMC: 1836998. DOI: 10.1136/bmj.299.6690.13. View

Duarte D, Minicucci M, Azevedo P, Chiuso-Minicucci F, Matsubara B, Matsubara L . Influence of lisinopril on cardiac remodeling induced by tobacco smoke exposure. Med Sci Monit. 2010; 16(8):BR255-9. View

Vegter S, de Jong-van den Berg L . Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010; 69(2):200-3. PMC: 2824482. DOI: 10.1111/j.1365-2125.2009.03571.x. View

10.

Hemels M, Bennett H, Bonari L, Han D, Traverso M, Einarson T . HOPE study impact on ACE inhibitors use. Ann Pharmacother. 2003; 37(5):640-5. DOI: 10.1345/aph.1C339. View

11.

Newcombe R . Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8):857-72. DOI: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e. View

12.

Singh N, Uppal M, Anuradha S, Agarwal A, Rizvi S . Angiotensin converting enzyme inhibitors and cough--a north Indian study. J Assoc Physicians India. 2001; 46(5):448-51. View

13.

Sharpe N . The HOPE TIPS: the HOPE study translated into practices. Cardiovasc Drugs Ther. 2005; 19(3):197-201. DOI: 10.1007/s10557-005-1375-1. View

14.

Lacourciere Y, Neutel J, Davidai G, Koval S . A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006; 19(1):104-12. DOI: 10.1016/j.amjhyper.2005.10.001. View

15.

Bicket D . Using ACE inhibitors appropriately. Am Fam Physician. 2002; 66(3):461-8. View

16.

Holecki M, Szewieczek J, Chudek J . Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure--are they important for doctors?. Pharmacol Rep. 2011; 63(3):740-51. DOI: 10.1016/s1734-1140(11)70586-2. View

17.

Visser L, Stricker B, Velden J, Paes A, Bakker A . Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol. 1995; 48(6):851-7. DOI: 10.1016/0895-4356(94)00231-e. View

18.

Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-59. DOI: 10.1056/NEJMoa0801317. View

19.

Hathial M . Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study. Indian Heart J. 2009; 60(3):200-4. View

20.

Sadanaga T, Yoshimura M, Sakamoto T, Sumida H, Ogawa H . Enalapril-induced cough is associated with non-severe heart failure. Int J Cardiol. 2008; 135(2):275-6. DOI: 10.1016/j.ijcard.2008.03.063. View